Andrea Mazzoleni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Mazzoleni has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Martin
Department of Biomedical Engineering University of Basel Basel Switzerland
5 shared publications - Manuele Giuseppe Muraro
Tissue Engineering Department of Biomedicine University of Basel and University Hospital of Basel Basel Switzerland
5 shared publications - Arnaud Scherberich
Department of Plastic, Reconstructive, Aesthetic, and Hand Surgery, University Hospital Basel, 4031 Basel, Switzerland
4 shared publications - Adrien Moya
Department of Biomedicine, University Hospital Basel, University of Basel, 4051 Basel, Switzerland
2 shared publications - Barbara Medagli
Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, Piazza dell’Ospitale 1, 34129 Trieste, Italy
2 shared publications - Benedetta Guagnini
Department of Medicine, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (33)
Vascularization of Human iPSC‐Derived Kidney Organoids Using Perfusion Culture, Pre‐Vascularized Collagen Scaffolds, and Decellularized Extracellular Matrix
Human induced pluripotent stem cell‐derived kidney organoids represent promising in vitro models for studying kidney development and drug‐induced toxicity, yet their lack of vasculature limits maturation and translational use. Here, we present a proof‐of‐concept co‐culture platform to promote vascularization of kidney organoids by integrating stromal vascular fraction cells, collagen sponge scaffolds, porcine kidney decellularized extracellular matrix (dECM), and dynamic culture in a perfusion‐based U‐CUP bioreactor. We systematically evaluated the effects of serum supplementation, scaffold pre‐vascularization, dECM encapsulation, and flow conditions on organoid–vascular integration. Low‐level serum supplementation (1.5% FBS) sustained vascular networks without compromising organoid morphology. Perfusion supported vascular expansion; however, while a low flow rate comparable to interstitial tissue flow (0.01 mL/min) preserved organoid morphology and glomerular‐like structures, a higher flow rate optimized for vascularization (0.47 mL/min) disrupted overall organoid architecture. Encapsulation within dECM preserved glomerular morphology and supported vascular infiltration, whereas co‐culture with stromal vascular fraction cells enabled putative podocyte–endothelial interactions. Finally, exposure to the calcineurin inhibitor tacrolimus revealed dose‐dependent cytotoxicity and characteristic nephron and vascular injury, demonstrating the model's utility for nephrotoxicity screening. The established modular platform enables the engineering of vascularized kidney organoids, establishing foundations for physiologically relevant models for disease modeling and pre‐clinical drug testing.
- 10 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (33)
Open AccessVascularization of Human iPSC‐Derived Kidney Organoids Using Perfusion Culture, Pre‐Vascularized Collagen Scaffolds, and Decellularized Extracellular Matrix
Human induced pluripotent stem cell‐derived kidney organoids represent promising in vitro models for studying kidney development and drug‐induced toxicity, yet their lack of vasculature limits maturation and translational use. Here, we present a proof‐of‐concept co‐culture platform to promote vascularization of kidney organoids by integrating stromal vascular fraction cells, collagen sponge scaffolds, porcine kidney decellularized extracellular matrix (dECM), and dynamic culture in a perfusion‐based U‐CUP bioreactor. We systematically evaluated the effects of serum supplementation, scaffold pre‐vascularization, dECM encapsulation, and flow conditions on organoid–vascular integration. Low‐level serum supplementation (1.5% FBS) sustained vascular networks without compromising organoid morphology. Perfusion supported vascular expansion; however, while a low flow rate comparable to interstitial tissue flow (0.01 mL/min) preserved organoid morphology and glomerular‐like structures, a higher flow rate optimized for vascularization (0.47 mL/min) disrupted overall organoid architecture. Encapsulation within dECM preserved glomerular morphology and supported vascular infiltration, whereas co‐culture with stromal vascular fraction cells enabled putative podocyte–endothelial interactions. Finally, exposure to the calcineurin inhibitor tacrolimus revealed dose‐dependent cytotoxicity and characteristic nephron and vascular injury, demonstrating the model's utility for nephrotoxicity screening. The established modular platform enables the engineering of vascularized kidney organoids, establishing foundations for physiologically relevant models for disease modeling and pre‐clinical drug testing.
- Open Access
- 11 June 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (26) , e05893
A Fully Human Engineered Bone Niche With Endogenous Osteoclastogenesis Reveals Osteoclast‐Dependent Osteomimicry in Prostate Cancer Cells
Bone is the predominant site of metastasis in advanced prostate cancer (PCa), yet the mechanisms governing tumor‐bone interactions remain incompletely understood, thanks in part to the scarcity of relevant models. The role played by osteoclasts in such interactions is especially obscure. A modular human three‐dimensional (3D) in vitro bone niche model was developedThe model integrates osteoblasts and osteoclasts within a mineralized scaffold, recreating an endosteal‐like microenvironment for co‐culture with PCa cell lines and patient‐derived organoids (PDOs). The engineered construct maintains osteoblastic differentiation and supports osteoclastogenesis, confirmed by lineage markers including osteocalcin, osteopontin (OPN), and tartrate‐resistant acid phosphatase (TRAP). Co‐culture with PCa cells downregulates osteoblast‐ and osteoclast‐associated genes (IBSP, OPN, TRAP) in bone cells, suggesting tumor‐mediated suppression of bone remodeling. Conversely, co‐cultured PCa cells exhibit niche‐dependent osteomimicry, characterized by upregulation of osteoblastic (SPARC, BGLAP) and osteoclastic (TRAP) markers and strongly regulated by the presence of osteoclasts. The platform also supports engraftment and proliferation of PDOs without exogenous PCa‐specific growth factors, underscoring its translational relevance. This osteoblastic‐osteoclastic niche model provides a human system that captures PCa‐bone cell interactions in a clinically relevant context, with potential utility for mechanistic and translational studies.
- 11 June 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (26) , e05893
Open AccessA Fully Human Engineered Bone Niche With Endogenous Osteoclastogenesis Reveals Osteoclast‐Dependent Osteomimicry in Prostate Cancer Cells
Bone is the predominant site of metastasis in advanced prostate cancer (PCa), yet the mechanisms governing tumor‐bone interactions remain incompletely understood, thanks in part to the scarcity of relevant models. The role played by osteoclasts in such interactions is especially obscure. A modular human three‐dimensional (3D) in vitro bone niche model was developedThe model integrates osteoblasts and osteoclasts within a mineralized scaffold, recreating an endosteal‐like microenvironment for co‐culture with PCa cell lines and patient‐derived organoids (PDOs). The engineered construct maintains osteoblastic differentiation and supports osteoclastogenesis, confirmed by lineage markers including osteocalcin, osteopontin (OPN), and tartrate‐resistant acid phosphatase (TRAP). Co‐culture with PCa cells downregulates osteoblast‐ and osteoclast‐associated genes (IBSP, OPN, TRAP) in bone cells, suggesting tumor‐mediated suppression of bone remodeling. Conversely, co‐cultured PCa cells exhibit niche‐dependent osteomimicry, characterized by upregulation of osteoblastic (SPARC, BGLAP) and osteoclastic (TRAP) markers and strongly regulated by the presence of osteoclasts. The platform also supports engraftment and proliferation of PDOs without exogenous PCa‐specific growth factors, underscoring its translational relevance. This osteoblastic‐osteoclastic niche model provides a human system that captures PCa‐bone cell interactions in a clinically relevant context, with potential utility for mechanistic and translational studies.
- Open Access
Dual-Lineage Human 3D Bone Niche Model Reveals Osteoclast-Driven Osteomimicry in Prostate Cancer
Bone is the predominant site of metastasis in advanced prostate cancer (PCa), yet the mechanisms governing tumor-bone interactions remain incompletely understood. A modular human three-dimensional (3D) in vitro bone niche model is developed that integrates osteoblasts and osteoclasts within a mineralized scaffold, recreating an endosteal-like microenvironment for co-culture with PCa cell lines and patient-derived organoids (PDOs). The engineered construct maintains osteoblastic differentiation and supports osteoclastogenesis, confirmed by lineage markers including osteocalcin, osteopontin (OPN), and tartrate-resistant acid phosphatase (TRAP). Co-culture with PCa cells downregulates osteoblast- and osteoclast-associated genes (IBSP, OPN, TRAP) in bone cells, suggesting tumor-mediated suppression of bone remodeling. Conversely, co-cultured PCa cells exhibit niche-dependent osteomimicry, characterized by upregulation of osteoblastic (SPARC, BGLAP) and osteoclastic (TRAP) markers and strongly regulated by the presence of osteoclasts. The platform also supports engraftment and proliferation of PDOs without PCa-specific exogenous growth factors, underscoring its translational relevance. This osteoblastic-osteoclastic niche model thus provides a human system capturing PCa-bone cell interactions, with potential utility to investigate therapeutic responses in a clinically relevant context. Table of Contents: A human 3D bone niche integrating osteoblasts and osteoclasts enables co-culture with prostate cancer cell lines and patient-derived organoids. The engineered niche (i) models reciprocal phenotypic regulation between bone and cancer cells, (ii) captures osteoclast-enhanced osteomimicry in tumor cells and (iii) establishes a biomimetic platform for mechanistic studies of metastatic prostate cancer cells in bone.
Open AccessDual-Lineage Human 3D Bone Niche Model Reveals Osteoclast-Driven Osteomimicry in Prostate Cancer
Bone is the predominant site of metastasis in advanced prostate cancer (PCa), yet the mechanisms governing tumor-bone interactions remain incompletely understood. A modular human three-dimensional (3D) in vitro bone niche model is developed that integrates osteoblasts and osteoclasts within a mineralized scaffold, recreating an endosteal-like microenvironment for co-culture with PCa cell lines and patient-derived organoids (PDOs). The engineered construct maintains osteoblastic differentiation and supports osteoclastogenesis, confirmed by lineage markers including osteocalcin, osteopontin (OPN), and tartrate-resistant acid phosphatase (TRAP). Co-culture with PCa cells downregulates osteoblast- and osteoclast-associated genes (IBSP, OPN, TRAP) in bone cells, suggesting tumor-mediated suppression of bone remodeling. Conversely, co-cultured PCa cells exhibit niche-dependent osteomimicry, characterized by upregulation of osteoblastic (SPARC, BGLAP) and osteoclastic (TRAP) markers and strongly regulated by the presence of osteoclasts. The platform also supports engraftment and proliferation of PDOs without PCa-specific exogenous growth factors, underscoring its translational relevance. This osteoblastic-osteoclastic niche model thus provides a human system capturing PCa-bone cell interactions, with potential utility to investigate therapeutic responses in a clinically relevant context. Table of Contents: A human 3D bone niche integrating osteoblasts and osteoclasts enables co-culture with prostate cancer cell lines and patient-derived organoids. The engineered niche (i) models reciprocal phenotypic regulation between bone and cancer cells, (ii) captures osteoclast-enhanced osteomimicry in tumor cells and (iii) establishes a biomimetic platform for mechanistic studies of metastatic prostate cancer cells in bone.
- Open Access
- 15 October 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (10) , 386
Fibronectin- and Bioactive Glass-Modified Alginate Scaffolds Support Limited Primary Cell Proliferation In Vitro yet Demonstrate Effective Host Integration In Vivo
Alginate-hydroxyapatite (AL) scaffolds modified with fibronectin (FN) or bioactive glass (BGMS10) have recently been characterized for their physicochemical properties and proposed as promising candidates for bone regeneration. Here, we present their first systematic biological evaluation, focusing on adhesion, proliferation, osteogenic differentiation, and in vivo host response. We compared FN-, BG-, and unmodified AL scaffolds using an immortalized mesenchymal stromal cell line (M-SOD) and primary human bone marrow-derived (BM-MSCs) and adipose-derived stromal cells (ASCs). FN scaffolds enhanced initial adhesion across all cell types and supported proliferation in M-SODs, but primary BM-MSCs and ASCs showed minimal expansion, regardless of scaffold type. BG scaffolds promoted expression of late-stage osteogenic markers in BM-MSCs, consistent with their ion release profile, but had limited impact on ASCs. In vivo subcutaneous implantation of acellular scaffolds in nude mice revealed robust host cell infiltration and extracellular matrix deposition across all scaffold types, confirming biocompatibility and integration. However, vascularization remained limited and did not differ substantially between formulations. Together, these findings highlight a critical discrepancy between immortalized and primary stromal cell responses to scaffold cues, underscoring the choice of cell source when evaluating the biocompatibility of a novel scaffold. At the same time, the effective in vivo integration observed across scaffold types emphasizes the importance of host tissue responses for translational evaluation of functional biomaterials.
- 15 October 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (10) , 386
Open AccessFibronectin- and Bioactive Glass-Modified Alginate Scaffolds Support Limited Primary Cell Proliferation In Vitro yet Demonstrate Effective Host Integration In Vivo
Alginate-hydroxyapatite (AL) scaffolds modified with fibronectin (FN) or bioactive glass (BGMS10) have recently been characterized for their physicochemical properties and proposed as promising candidates for bone regeneration. Here, we present their first systematic biological evaluation, focusing on adhesion, proliferation, osteogenic differentiation, and in vivo host response. We compared FN-, BG-, and unmodified AL scaffolds using an immortalized mesenchymal stromal cell line (M-SOD) and primary human bone marrow-derived (BM-MSCs) and adipose-derived stromal cells (ASCs). FN scaffolds enhanced initial adhesion across all cell types and supported proliferation in M-SODs, but primary BM-MSCs and ASCs showed minimal expansion, regardless of scaffold type. BG scaffolds promoted expression of late-stage osteogenic markers in BM-MSCs, consistent with their ion release profile, but had limited impact on ASCs. In vivo subcutaneous implantation of acellular scaffolds in nude mice revealed robust host cell infiltration and extracellular matrix deposition across all scaffold types, confirming biocompatibility and integration. However, vascularization remained limited and did not differ substantially between formulations. Together, these findings highlight a critical discrepancy between immortalized and primary stromal cell responses to scaffold cues, underscoring the choice of cell source when evaluating the biocompatibility of a novel scaffold. At the same time, the effective in vivo integration observed across scaffold types emphasizes the importance of host tissue responses for translational evaluation of functional biomaterials.
- Open Access
- 29 August 2025
- Published by MDPI AG in Preprints.org
Fibronectin- and Bioactive Glass-Modified Alginate Scaffolds Support Limited Primary Cell Proliferation In Vitro yet Demonstrate Effective Host Integration In Vivo
Alginate-hydroxyapatite (AL) scaffolds modified with fibronectin (FN), or bioactive glass (BGMS10) have recently been characterized for their physicochemical properties and proposed as promising candidates for bone regeneration. Here, we present their first systematic biological evaluation, focusing on adhesion, proliferation, osteogenic differentiation in vitro, and in vivo host response. We compared FN-, BG-, and unmodified AL scaffolds using an immortalized mesenchymal stromal cell line (M-SOD) and primary human bone marrow-derived (BM-MSCs) and adipose-derived stromal cells (ASCs). FN scaffolds enhanced initial adhesion across all cell types and supported proliferation in M-SODs, while primary BM-MSCs and ASCs showed minimal expansion, regardless of scaffold type. BG scaffolds promoted expression of late-stage osteogenic markers in BM-MSCs, consistent with their ion release profile, but had limited impact on ASCs. In vivo subcutaneous implantation of acellular scaffolds in nude mice revealed robust host cell infiltration and extracellular matrix deposition across all scaffold types, confirming biocompatibility and integration. However, vascularization remained limited and did not differ substantially between formulations. Together, these findings highlight a critical discrepancy between immortalized and primary stromal cell response to scaffold cues, underscoring the challenge of sustaining primary cell proliferation in vitro. At the same time, the effective in vivo integration observed across scaffold types emphasizes the importance of host tissue responses for translational evaluation of functional biomaterials.
- 29 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFibronectin- and Bioactive Glass-Modified Alginate Scaffolds Support Limited Primary Cell Proliferation In Vitro yet Demonstrate Effective Host Integration In Vivo
Alginate-hydroxyapatite (AL) scaffolds modified with fibronectin (FN), or bioactive glass (BGMS10) have recently been characterized for their physicochemical properties and proposed as promising candidates for bone regeneration. Here, we present their first systematic biological evaluation, focusing on adhesion, proliferation, osteogenic differentiation in vitro, and in vivo host response. We compared FN-, BG-, and unmodified AL scaffolds using an immortalized mesenchymal stromal cell line (M-SOD) and primary human bone marrow-derived (BM-MSCs) and adipose-derived stromal cells (ASCs). FN scaffolds enhanced initial adhesion across all cell types and supported proliferation in M-SODs, while primary BM-MSCs and ASCs showed minimal expansion, regardless of scaffold type. BG scaffolds promoted expression of late-stage osteogenic markers in BM-MSCs, consistent with their ion release profile, but had limited impact on ASCs. In vivo subcutaneous implantation of acellular scaffolds in nude mice revealed robust host cell infiltration and extracellular matrix deposition across all scaffold types, confirming biocompatibility and integration. However, vascularization remained limited and did not differ substantially between formulations. Together, these findings highlight a critical discrepancy between immortalized and primary stromal cell response to scaffold cues, underscoring the challenge of sustaining primary cell proliferation in vitro. At the same time, the effective in vivo integration observed across scaffold types emphasizes the importance of host tissue responses for translational evaluation of functional biomaterials.